pd-1

Novartis gives up on tislelizumab, BeiGene’s PD-1 inhibitor approved in Europe

Novartis has terminated its significant cancer immunotherapy collaboration with BeiGene, ending a partnership that had granted Novartis co-development and co-commercialization ...